Research information, not medical advice. This page summarises published evidence and registered trials so that you can look further; it does not assess your situation. Talk to your own clinician before acting on anything here. How we select and grade sources
Based on: Rheumatoid Arthritis — gene targets, candidate compounds and trials, OSMF Research Tracker (DGIdb, Open Targets, ChEMBL, PubMed and ClinicalTrials.gov data). Numbers are a snapshot taken 28 October 2026; the tracker page is the live version.
Full trial data → The Rheumatoid Arthritis pipeline page on the Research Tracker has every candidate, gene target and trial, with evidence grades.
Short answer: as of October 2026, the OSMF Research Tracker lists 50 candidate medicines for rheumatoid arthritis that are either approved medicines or have at least one registered clinical trial, built on 13 druggable gene targets, with 15 recent trials on ClinicalTrials.gov. 9 are already approved medicines, for this condition or another one; where the approval is for a different condition, the trial is testing a new use, which is what drug repurposing means. Being in a trial says an intervention is being studied, not that it works; that is what the trial is for.
Which candidates have the most trial activity?
Ranked by the number of registered trials the tracker found. Each trial ID links to the registry entry, where you can read the design, status and sponsor.
- adalimumab — 4 registered trials · approved medicine · NCT01185301 NCT00690573 NCT01592292
- Etanercept — 3 registered trials · approved medicine · NCT01623752 NCT01592292
- PF-04629991 — 3 registered trials · in clinical trials · NCT00797342
- Sirukumab — 3 registered trials · in clinical trials · NCT01606761
- abatacept — 2 registered trials · approved medicine · NCT00547521 NCT04909801
- methotrexate — 2 registered trials · approved medicine · NCT01185301 NCT04909801
- Rituximab — 2 registered trials · approved medicine · NCT00664521 NCT01592292
- ianalumab (VAY736) — 2 registered trials · in clinical trials · NCT05349214 NCT05350072
- Treatment A — 2 registered trials · in clinical trials · NCT01184001
- Treatment B — 2 registered trials · in clinical trials · NCT01184001
- etanercept (CHS-0214) — 1 registered trial · approved medicine · NCT02486939
- Filgotinib — 1 registered trial · approved medicine · NCT04985435
Which gene targets are these built on?
The tracker starts from genes with evidence of being druggable in rheumatoid arthritis and asks which compounds act on them. Each symbol links to its DGIdb entry, which lists the interacting drugs and the papers behind them: CD80, IL17A, IL1B, IL6, IL6R, JAK1, JAK2, JAK3, MMP3, MS4A1, PTPN22, TNF, TNFSF11.
Which trials are registered?
Drug and biologic treatment trials whose main condition is rheumatoid arthritis, from the tracker's ClinicalTrials.gov snapshot. Full trial data →
- Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants NCT07201558 · Recruiting · Phase 1 · started 2025-12-02
- Efficacy of JAK STAT Pathways Inhibitors in Treatment of Patients With Rheumatoid Arthritis NCT05788705 · Completed · started 2025-04-05
- A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY) NCT07409103 · Recruiting · Phase 2 · started 2026-02-18
- Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion and Intra-Articular Injection for RA NCT05003934 · Recruiting · Phase 1 · started 2021-11-07
- A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis NCT06994143 · Recruiting · Phase 1 · started 2025-05-19
- A Study With CIT-013 in RA Patients NCT06567470 · Completed · Phase 2 · started 2025-07-29
- An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis NCT07620392 · Recruiting · Phase 2 · started 2026-06-03
- A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) NCT07137598 · Recruiting · Phase 2 · started 2025-12-05
- A Study of F8IL10 Intra-articular Treatment in Rheumatoid Arthritis NCT07245992 · Recruiting · Phase 1 · started 2026-03-04
- Phase 1b/2 Study of IV Sarilumab in Adult With RA NCT07704580 · Recruiting · Phase 1/2 · started 2026-07-02
- A Trial in Healthy Adult Participants and Adults With Autoimmune Disease to Test How HBM7020 is Tolerated and Absorbed in the Body NCT07649265 · Recruiting · Phase 1 · started 2026-09-24
- A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis NCT07276581 · Recruiting · Phase 2 · started 2025-12-15
- A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [Proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid Arthritis NCT06596772 · Completed · Phase 3 · started 2024-10-03
- A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis NCT06972446 · Recruiting · Phase 2 · started 2025-06-20
- MethMax Trial: MAXimising the METHotrexate Therapy Potential in Patients With Active Rheumatoid Arthritis NCT06649136 · Recruiting · Phase 4 · started 2024-08-12
How to read this
Evidence is graded on the tracker page in three tiers: clinical (tested in people), mechanistic (a documented action on the target) and correlative (an association in the literature). Most candidates sit in the lower tiers, and many trials are small or early-phase. The list is restricted to medicines and supplements: trial arms that are devices, procedures, behavioural programmes or measurements are filtered out automatically, so an occasional misclassified entry is possible; the tracker page lists every arm. The purpose of this list is to show where the research is, with sources, so that patients, clinicians and researchers can look further; it is not a ranking of what to take. How sources are chosen, graded and corrected is set out in our editorial policy.
Related on this site
Research information, not medical advice. Decisions about any medicine belong with you and your clinician. The underlying data are open (CC BY 4.0) and refreshed daily; this note was generated from the tracker page on 28 October 2026.